FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to versions of a stable pharmaceutical composition containing an anti-LAG3 antibody, an anti-PD-1 antibody, sucrose, polysorbate 80, histidine buffer, L-arginine or its pharmaceutically acceptable salt and L-methionine.
EFFECT: reduced self-association, improved colloidal stability of anti-LAG3 antibody, as well as improved stability of joint formulations of anti-PD-1 and anti-LAG3 antibodies.
14 cl, 51 dwg, 20 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-ORAI1 ANTIBODY | 2015 |
|
RU2724742C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| ANTI-CDH6-ANTIBODY AND ANTI-CDH6-ANTIBODY-DRUG CONJUGATE | 2018 |
|
RU2798285C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTI-CD39 ANTIBODIES, COMPOSITIONS CONTAINING ANTI-CD39 ANTIBODIES AND METHODS OF APPLICATION OF ANTI-CD39 ANTIBODIES | 2018 |
|
RU2795348C2 |
